<DOC>
	<DOCNO>NCT02272738</DOCNO>
	<brief_summary>The purpose study evaluate clinical safety efficacy Gemcitabine plus nab-Paclitaxel chemoradiotherapy determine Maximal Tolerated Dose ( MTD ) unresectable locally advanced pancreatic adenocarcinoma .</brief_summary>
	<brief_title>A Study Chemoradiotherapy Using Gem Plus Nab-paclitaxel Pancreatic Cancer</brief_title>
	<detailed_description>Gemcitabine plus nab-Paclitaxel one standard chemotherapy metastatic pancreatic adenocarcinoma . Gemcitabine plus nab-Paclitaxel realize favorable anti-tumor effect tolerable toxicity . Gemcitabine plus nab-Paclitaxel promising regimen concurrent chemoradiotherapy , investigator need know safety case concurrent chemoradiotherapy .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm advanced pancreatic cancer Locally advance pancreatic cancer define presence surgically unresectable tumor ( involve celiac axis superior mesenteric artery ) Performance Status:01 ( ECOG ) Patients age = &gt; 20 75 &gt; White Blood Cell ( WBC ) &gt; =3,500/mm3,12,000/mm3 , Neutrophils &gt; =1,500/mm3 , platelets=100,000/mm3 , Hemoglobin &gt; =9.5 g/dl , GOT &lt; /=2.0 X Upper Limit Number ( ULN ) , Glutamate Pyruvate Transaminase ( GPT ) &lt; /=2.0 X ULN , Alkaline Phosphatase ( ALP ) &lt; /=2.0 X ULN , Total bilirubin &lt; =1.5mg/dl , Serum creatinine &lt; =1.2mg/dl , Creatinine clearance &gt; =50 ml/min arterial O2 pressure ( PaO2 ) &gt; =70torr arterial O2 saturation ( SpO2 ) &gt; =96 % Life expectancy 3 month . Written informed consent . Active infection Lung fibrosis intestinal pneumonia detectable chest Xray CT Severe complication ( heart disease , cirrhosis , diabetes ) Myocardial infarction within 3 month Active synchronous metachronous malignancy Pregnant lactation woman , woman know suspected pregnancy Symptomatic brain metastasis History severe drug allergy Peripheral neuropathy Patients judge inappropriate entry study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>